Neuroimaging Correlates of Alzheimer's Disease Variants

Alzheimer’s disease encompasses a spectrum of clinical variants distinguished by regional patterns of neuronal injury and protein deposition. Neuroimaging modalities such as structural magnetic resonance imaging (MRI), fluorodeoxyglucose positron emission tomography (FDG-PET), amyloid-PET and tau-PET reveal distinct profiles of cortical atrophy and metabolic dysfunction corresponding to subtypes that include typical amnestic Alzheimer’s, hippocampal-sparing, limbic-predominant, posterior cortical atrophy, logopenic primary progressive aphasia and progressive dysexecutive syndrome. Visual rating scales and quantitative measures of cortical thickness or hypometabolism enable classification of these variants, which differ in age of onset, cognitive trajectory and response to emerging treatments. A biomarker framework integrating amyloid, tau and neurodegeneration (‘A/T/N’) captures the heterogeneity of neurodegenerative burden and guides personalised prognosis. Such imaging correlates inform early differential diagnosis, stratification in clinical trials and the development of tailored interventions, emphasising the global need for precision approaches in dementia care.

Research from Nature Portfolio

Recent advances have refined imaging-based classification of Alzheimer’s subtypes. Validation of visual rating scales demonstrated reliable identification of typical, limbic-predominant and hippocampal-sparing patterns, revealing divergent longitudinal trajectories and differential reliance on non-memory cognitive domains. A graph-theory approach to cortical atrophy mapped three reproducible clusters—parietal-predominant, medial temporal-predominant and diffuse—each with distinct cognitive profiles and severity. Complementing these efforts, evaluation of the A/T/N biomarker scheme in mild cognitive impairment linked cerebrospinal fluid amyloid and tau status with specific MRI atrophy patterns, predicting progression risk and underscoring variation within the neurodegeneration domain. Together, these studies establish robust imaging and biomarker criteria for subtype-targeted research and clinical decision making.

Neuroimaging Correlates of Alzheimer's Disease Variants publication trend

The graph below shows the total number of articles in neuroimaging correlates of alzheimer's disease variants across all publications each year (not limited to Nature Index journals).

Technical terms

Structural magnetic resonance imaging (MRI): Non-invasive technique using magnetic fields to visualise and quantify brain anatomy and cortical thickness.

Positron emission tomography (PET): Molecular imaging method employing radiolabelled tracers to measure metabolic activity or protein deposition (e.g., FDG for glucose metabolism, amyloid- or tau-ligands).

Cortical atrophy: Regional thinning or volume loss of the cerebral cortex, indicative of neurodegeneration in specific Alzheimer’s subtypes.

A/T/N biomarker scheme: Classification framework denoting amyloid pathology (A), tau pathology (T) and neurodegeneration (N) to stratify disease stage and variant.

Visual rating scales: Standardised scores assigned by experts to images of hippocampal, parietal or frontal regions to classify atrophy patterns in clinical settings.

References

1. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis. The Lancet Neurology (2024).
2. Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease. JAMA Neurology (2024).
3. Biomarkers in Alzheimer’s disease: role in early and differential diagnosis and recognition of atypical variants. Alzheimer's Research & Therapy (2023).
4. Distinct subtypes of Alzheimer’s disease based on patterns of brain atrophy: longitudinal trajectories and clinical applications. Scientific Reports (2017).
5. Robust Identification of Alzheimer’s Disease subtypes based on cortical atrophy patterns. Scientific Reports (2017).
6. The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment. Scientific Reports (2018).